BioSpace News Archive

Mainz Biomed N.V. today announced the underwriters have exercised their over-allotment option resulting in the issuance of an additional 300,000 shares.

Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the following upcoming investor conferences.

AVITA Medical, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, reported financial results for its first fiscal quarter ended September 30, 2021.

NexImmune, Inc. (Nasdaq: NEXI), today announced it plans to report third quarter financial results and provide a corporate update on Friday, November 12, 2021, via press release, prior to the market open.

Histogen Inc., a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, announced that that Steven J. Mento, Ph.D., a current member of the Histogen Board of Directors, has been appointed Executive Chairman and Interim President and Chief Executive Officer effective immediately.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate activities for the quarter ended September 30, 2021.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report third quarter 2021 financial results on Monday, November 15, 2021.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), congratulates partner Neurona Therapeutics on clearance by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application to initiate its first-in-human Phase 1/2 clinical trial evaluating the safety and efficacy of NRTX-1001 in patients with drug-resistant mesial temporal lobe epilepsy (MTLE).

Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients

Medexus Pharmaceuticals Inc. announced that it has appointed Ian C Wildgoose Brown as the Company’s general counsel and corporate secretary.